← Leaderboards
Nathan Herrmann
Medical University Of South Carolina
$1,621,416
Attributed
$8,107,079
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2014–18$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$8,107,079 · 1
By mechanism
R01$8,107,079 · 1
Top collaborators
- Krista L. Lanctot10 shared
- Jacobo E. Mintzer10 shared
- Paul B Rosenberg10 shared
- Roberta W Scherer9 shared
- David M Shade1 shared
Most similar at Medical University Of South Carolina
Same institution · by research overlap
- Kathleen Theresa Brady$137,017,915
- Howard C. Becker$27,005,125
- W Timothy Garvey$15,668,226
- Jacqueline F. McGinty$25,740,455
- John J Woodward$26,772,252
Others in their field
Top investigators on “Dependence”
- Jeffrey P Krischer · University Of South Florida$600,613,482
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$177,347,135
- John M Lachin · George Washington University$151,703,760
- David M Nathan · Massachusetts Institute Of Technology$139,667,524
- Christopher McKay · Battelle Memorial Institute$134,148,552
- Katherine M Thibault · Battelle Memorial Institute$134,148,552
Research focus
DependenceCognitive FunctionDementiaCooperative StudyAdverse EventAgitationAdverse OutcomeAttentionActivities Of Daily LivingAdverse EffectsAffectiveBiologyCaregiver BurdenCaregiversCholinesterase InhibitorsAlzheimer&AposClinically SignificantClinical PracticeAffectClinical TrialsCognitionCognitiveBehavior MeasurementDirect Costs
Grant awards (10)
Apathy in Alzheimer's Disease Methyphenidate Trial II (ADMET II)$1,297,999
R01 · FY2018 · AG
Apathy in Alzheimer's Disease Methyphenidate Trial II (ADMET II)$367,383
R01 · FY2018 · AG
Apathy in Alzheimer's Disease Methyphenidate Trial II (ADMET II)$172,427
R01 · FY2018 · AG
Apathy in Alzheimer's Disease Methyphenidate Trial II (ADMET II)$100,000
R01 · FY2018 · AG
Apathy in Alzheimer's Disease Methyphenidate Trial II (ADMET II)$1,455,745
R01 · FY2017 · AG
Apathy in Alzheimer's Disease Methyphenidate Trial II (ADMET II)$144,804
R01 · FY2017 · AG
Apathy in Alzheimer's Disease Methyphenidate Trial II (ADMET II)$1,451,083
R01 · FY2016 · AG
Apathy in Alzheimer's Disease Methyphenidate Trial II (ADMET II)$100,000
R01 · FY2016 · AG
Apathy in Alzheimer's Disease Methyphenidate Trial II (ADMET II)$1,426,649
R01 · FY2015 · AG
Apathy in Alzheimer's Disease Methyphenidate Trial II (ADMET II)$1,590,989
R01 · FY2014 · AG